Single-nucleotide polymorphisms in the p53 signaling pathway.

TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92

p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34

An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev (2016) 1.70

The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52

Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. PLoS One (2015) 1.45

Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J (2011) 1.24

Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog (2011) 1.07

The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer (2016) 0.98

Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc Natl Acad Sci U S A (2011) 0.97

A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res (2012) 0.93

Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell (2012) 0.84

Clinical significance in oral cavity squamous cell carcinoma of pathogenic somatic mitochondrial mutations. PLoS One (2013) 0.84

TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population. BMC Cancer (2013) 0.82

p53: out of Africa. Genes Dev (2016) 0.79

The pharmacogenomics of osteosarcoma. Pharmacogenomics J (2016) 0.79

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. PLoS One (2014) 0.78

p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress. Front Oncol (2015) 0.77

p53 downregulates the Fanconi anaemia DNA repair pathway. Nat Commun (2016) 0.77

Systems approaches to molecular cancer diagnostics. Discov Med (2010) 0.76

Ataxia Telangiectasia-Mutated (ATM)Polymorphisms and Risk of Lung Cancer in a Chinese Population. Front Public Health (2017) 0.75

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica (2014) 0.75

Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression. Int J Exp Pathol (2016) 0.75

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. Lung Cancer (Auckl) (2011) 0.75

A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer (2017) 0.75

p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04

Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26

The biochemistry of apoptosis. Nature (2000) 18.91

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53

ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer (2003) 16.06

Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 12.39

Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90

Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05

Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 10.89

p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21

Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (1995) 8.53

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18

Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86

A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35

Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet (2003) 6.46

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer (2008) 6.22

p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev (1995) 5.63

The many substrates and functions of ATM. Nat Rev Mol Cell Biol (2000) 5.46

The P53 pathway: what questions remain to be explored? Cell Death Differ (2006) 4.91

KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer (2006) 4.14

p53 regulates maternal reproduction through LIF. Nature (2007) 4.12

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06

The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50

p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49

Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26

Regulation of p53 function and stability by phosphorylation. Mol Cell Biol (1999) 3.24

A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 3.13

A variation in the structure of the protein-coding region of the human p53 gene. Gene (1988) 3.03

ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet (1998) 3.01

Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87

TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69

CHK2 kinase--a busy messenger. Nat Rev Mol Cell Biol (2001) 2.68

Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst (2004) 2.66

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65

Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer (2006) 2.41

P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer (2000) 2.35

Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev (2006) 2.35

Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 2.31

Genetic analysis of radiation-induced changes in human gene expression. Nature (2009) 2.30

Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20

p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer (2004) 2.18

Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol (1986) 2.14

P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med (2008) 2.10

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene (2007) 1.92

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol (2008) 1.91

Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A (2009) 1.79

The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene (1997) 1.79

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet (2005) 1.78

Unleashing the power of p53: lessons from mice and men. Genes Dev (2006) 1.76

TP53 family members and human cancers. Hum Mutat (2003) 1.70

A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res (2007) 1.67

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64

ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem (2002) 1.56

The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res (2005) 1.56

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev (2007) 1.52

Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst (2006) 1.51

Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer (2006) 1.51

Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci U S A (2005) 1.49

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem (2005) 1.47

Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res (2008) 1.37

MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet (2006) 1.35

The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet (2005) 1.34

The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet (2006) 1.32

Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A (2007) 1.28

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res (2007) 1.25

MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis (2008) 1.25

A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene (1994) 1.18

Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts. PLoS Genet (2009) 1.17

Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis (2004) 1.17

Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists. Cancer Epidemiol Biomarkers Prev (2007) 1.16

Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res (2009) 1.15

p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res (2004) 1.14

p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. Reprod Biomed Online (2006) 1.14

Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol (2008) 1.13

Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res (2008) 1.13

The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem (2003) 1.12

A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res (2004) 1.11

A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer (2004) 1.11

Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis (2008) 1.11

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res (2007) 1.11

TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet (2009) 1.10

What have animal models taught us about the p53 pathway? J Pathol (2005) 1.09

The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Hum Mutat (2006) 1.09

p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.08

CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer (2008) 1.06

Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04

Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int J Cancer (2006) 1.04

The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev (2008) 1.02

MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer (2006) 1.02

Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res (2009) 1.01

Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol (2005) 1.01

Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res (2005) 1.00

The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03

A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell (2013) 2.60

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54

A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem (2005) 1.47

MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet (2006) 1.35

Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A (2007) 1.28

Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res (2009) 1.13

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res (2012) 1.09

A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res (2012) 0.93

Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. Clin Cancer Res (2009) 0.92

MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation. Pancreas (2010) 0.88

An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One (2008) 0.83

A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer (2011) 0.83

Hereditary and environmental epidemiology of sarcomas. Clin Sarcoma Res (2012) 0.80

SNPing away at human skin color. Pigment Cell Melanoma Res (2014) 0.75

Radiation-induced apoptosis varies among individuals and is modified by sex and age. Int J Radiat Biol (2014) 0.75

Acute abdominal pain in patients with systemic lupus erythematosus. J Gastrointest Surg (2009) 0.75

Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. Pancreas (2017) 0.75